Health-care companies rose amid earnings optimism. Eli Lilly added to gains, amid a sense that the maker of Mounjaro and Zepbound is pulling away from its competition in the obesity-drug boom. Shares ...

Pfizer said on Friday it had filed a lawsuit against Metsera and Novo Nordisk , saying Metsera breached its merger agreement ...

Plus, the Trump administration is expected to release finalized Medicare payment rules for doctors and hospitals as soon as ...

Pharmaceutical titan Eli Lilly has delivered a quarterly report that dramatically surpassed market forecasts, sending waves ...

This proprietary system employs specialized algorithms to identify early signs of litigation trends in federal litigation filings. Click here to learn more about Law.com Radar's new suit alerting and ...

Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin ...

TLDR Novo Nordisk launched an unsolicited $9 billion offer for Metsera, trumping Pfizer’s existing $7.3 billion acquisition ...

"Massive sales for weight loss drugs spur Eli Lilly’s Q3" was originally created and published by Pharmaceutical Technology, ...

Major stock indexes declined Thursday as investors digested several big tech earnings reports and awaited more after the ...

The U.S. stock market sank from its record heights on Thursday, as Wall Street sifted through mixed developments on ...

Eli Lilly announced that its experimental weight-loss pill, orforglipron, meets most of the criteria for the U.S. Food and ...